Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Omnicell (OMCL) Acquisitions (2012 - 2022)

Omnicell (OMCL) reported Acquisitions of $3.4 million for Q1 2022, down 98.07% on a QoQ basis from $176.1 million in Q4 2021.

Omnicell (OMCL) has 8 years of Acquisitions data on file, last reported at $3.4 million in Q1 2022.

  • Quarterly Acquisitions changed N/A year-over-year to $3.4 million in Q1 2022, while the trailing twelve-month figure through Dec 2022 was $3.4 million (down 99.04% YoY) and the FY2022 annual result came in at $3.4 million, down 99.04% from the prior year.
  • Acquisitions retreated to $3.4 million in Q1 2022 per OMCL's latest filing, from $176.1 million in the prior quarter.
  • Across five years, Acquisitions topped out at $225.0 million in Q4 2020 and bottomed at $3.4 million in Q1 2022.
  • The 3-year median for Acquisitions is $177.1 million (2021), against an average of $145.6 million.
  • Peak annual rise in Acquisitions reached 21.74% in 2021, while the deepest fall reached 21.74% in 2021.
  • Tracing OMCL's Acquisitions over 3 years: stood at $225.0 million in 2020, then retreated by 21.74% to $176.1 million in 2021, then slumped by 98.07% to $3.4 million in 2022.
  • Per Business Quant, the three latest OMCL Acquisitions figures stand at $3.4 million (Q1 2022), $176.1 million (Q4 2021), and $178.1 million (Q3 2021).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Acquisitions (Qtr)
1 Veeva Systems 30.85 Bn 24.28 Bn 622.47 Mn -
2 BrightSpring Health Services 12.29 Bn 11.41 Bn 482.22 Mn 42.20 Mn
3 Healthequity 7.80 Bn 7.48 Bn 256.31 Mn -
4 Hinge Health 4.82 Bn 4.51 Bn 154.23 Mn -
5 Doximity 4.21 Bn 3.46 Bn 125.97 Mn -
6 Waystar Holding 4.18 Bn 4.03 Bn 268.04 Mn 2.04 Mn
7 10x Genomics 3.78 Bn 3.24 Bn 106.18 Mn -
8 Privia Health 2.65 Bn 2.28 Bn 595.71 Mn -
9 Omnicell 1.95 Bn 1.78 Bn 140.36 Mn -
10 Teladoc Health 1.42 Bn 672.39 Mn 562.57 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2022 3.39 Mn
Dec 31, 2021 176.08 Mn
Sep 30, 2021 178.08 Mn
Dec 31, 2020 225.00 Mn
Jun 30, 2017 4.45 Mn
Dec 31, 2016 40.70 Mn
Mar 31, 2016 271.46 Mn
Dec 31, 2015 52,000.00
Sep 30, 2015 1.83 Mn
Jun 30, 2015 -14.01 Mn
Dec 31, 2014 974,000.00
Sep 30, 2014 19.75 Mn
Jun 30, 2012 156.31 Mn